Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - tocilizumab, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; sucrose; monobasic sodium phosphate dihydrate; dibasic sodium phosphate dodecahydrate; water for injections - rheumatoid arthritis (iv and sc formulations), actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients in combination with methotrexate (mtx) or other non-biological disease-modifying anti-rheumatic drugs (dmards) in case of either an inadequate response or intolerance to previous therapy with one or more dmards. actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with poor prognostic factors (see section 5.1 pharmacodynamic properties, clinical trials) in combination with mtx in those not previously treated with mtx. in the two groups of patients above, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra has been shown to inhibit the progression of joint damage in adults, as measured by x-ray, when given in combination with methotrexate.,polyarticular juvenile idiopathic arthritis (iv and sc formulations), actemra is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to or intolerance to methotrexate (mtx). actemra can be given alone or in combination with mtx.,systemic juvenile idiopathic arthritis (iv and sc formulations), intravenous formulation, actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. subcutaneous formulation actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older. actemra iv and sc can be given alone or in combination with methotrexate (mtx).,cytokine release syndrome (crs) (iv formulation only), actemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. coronavirus disease 2019 (covid-19) (iv formulation only),actemra has provisional approval for the treatment of coronavirus disease 2019 (covid-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. provisional approval has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - tocilizumab, quantity: 400 mg - injection, concentrated - excipient ingredients: sucrose; polysorbate 80; monobasic sodium phosphate dihydrate; water for injections; dibasic sodium phosphate dodecahydrate - rheumatoid arthritis (iv and sc formulations),actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients in combination with methotrexate (mtx) or other non-biological disease-modifying anti-rheumatic drugs (dmards) in case of either an inadequate response or intolerance to previous therapy with one or more dmards. actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with poor prognostic factors (see section 5.1 pharmacodynamic properties, clinical trials) in combination with mtx in those not previously treated with mtx. in the two groups of patients above, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra has been shown to inhibit the progression of joint damage in adults, as measured by x-ray, when given in combination with methotrexate. polyarticular juvenile idiopathic arthritis (iv and sc formulations), actemra is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to or intolerance to methotrexate (mtx). actemra can be given alone or in combination with mtx.,systemic juvenile idiopathic arthritis (iv and sc formulations), intravenous formulation, actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. subcutaneous formulation actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older.actemra iv and sc can be given alone or in combination with methotrexate (mtx).,cytokine release syndrome (crs) (iv formulation only), actemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. coronavirus disease 2019 (covid-19) (iv formulation only),actemra has provisional approval for the treatment of coronavirus disease 2019 (covid-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. provisional approval has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - tixagevimab 100 mg/ml;  ; cilgavimab 100 mg/ml;   - solution for injection - 100 mg/ml - active: tixagevimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection active: cilgavimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection - evusheld is indicated for the pre-exposure prophylaxis of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg, - who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to covid-19 vaccination or - for whom vaccination with any approved covid-19 vaccine is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a covid-19 vaccine(s) and/or covid-19 vaccine component(s).

United States - English - NLM (National Library of Medicine)

eli lilly and company - baricitinib (unii: isp4442i3y) (baricitinib - unii:isp4442i3y) - olumiant® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (tnf) blockers. limitations of use : not recommended for use in combination with other jak inhibitors, biologic disease-modifying antirheumatic drugs (dmards), or with potent immunosuppressants such as azathioprine and cyclosporine. olumiant is indicated for the treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo). olumiant is indicated for the treatment of adult patients with severe alopecia areata. limitations of use : not recommended for use in combination with other jak inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. none. risk summary based on the findings from animal reproduction studies, olumiant may cause fetal harm duri

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tixagevimab, quantity: 150 mg - injection, solution - excipient ingredients: sucrose; polysorbate 80; water for injections; histidine; histidine hydrochloride monohydrate - pre-exposure prophylaxis,evusheld (tixagevimab and cilgavimab) has provisional approval for the pre-exposure prophylaxis of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg,,- who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to covid-19 vaccination or,- for whom vaccination with any approved covid-19 vaccine is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a covid-19 vaccine(s) and/or covid-19 vaccine component(s).,see section 4.2 dose and method of administration and section 5.2 pharmacokinetic properties.,evusheld is not recommended as a substitute for vaccination in individuals for whom covid-19 vaccination is recommended.,this decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer-term efficacy and safety data from ongoing clinical trials.,treatment,evusheld has provisional approval for the treatment of adults with covid-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19. see section 4.2 dose and method of administration and section 5.2 pharmacokinetic properties.,this decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer-term efficacy and safety data from ongoing clinical trial.

United States - English - NLM (National Library of Medicine)

spry life llc - organic calendula officinalis (calendula) flower oil 1x (hpus) organic plantago major (plantain) leaf extract 1x (hpus), organic olea europaea (olive) leaf oil 1x (hpus), organicachilleamillefolium(yarrow)extract1x(hpus) - skin protectant astringent • temporarily protects minor • cuts • scrapes • abrasions • bruises • blisters • burns ▪︎ temporarily protects and helps relieve • chapped or cracked skin ▪︎ helps protect from the drying effects of wind and cold weather ▪︎ temporarily protects and helps relieve minor skin irritations and itching due to • cracked hands and cracked feet • minor rashes • rashes caused by soaps, detergents, cosmetics, or jewelry

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e) - influenza a virus 35 [hp_x] in 1 g

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e) - influenza a virus 35 [hp_x] in 1 ml

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e) - influenza a virus 30 [hp_x] in 1 ml

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e) - influenza a virus 30 [hp_x] in 1 g